AMEX · CATX
Healthcare · Medical - Devices
$2.99
Down-$0.22 (-7.36%)
Updated Sep 11, 2026, 12:36 AM
SID Score
3.8/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 19 trading sessions · Daily adjusted prices
CATX closed at $2.99 after 19 trading sessions, down 3.55% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 9, 2026 | $3.07 | $3.1075 | $2.96 | $2.99 | 1.5M |
| Sep 8, 2026 | $3.12 | $3.18 | $3.02 | $3.12 | 1.06M |
| Sep 4, 2026 | $3.07 | $3.18 | $3.025 | $3.13 | 1.37M |
| Sep 3, 2026 | $3.09 | $3.14 | $3.03 | $3.12 | 931.7K |
| Sep 2, 2026 | $3.10 | $3.235 | $3.025 | $3.10 | 864.64K |
| Sep 1, 2026 | $3.16 | $3.165 | $3.07 | $3.10 | 705.84K |
| Aug 31, 2026 | $3.11 | $3.18 | $3.08 | $3.16 | 910.73K |
| Aug 28, 2026 | $3.16 | $3.17 | $3.075 | $3.11 | 913.34K |
| Aug 27, 2026 | $3.15 | $3.24 | $3.10 | $3.18 | 797.53K |
| Aug 26, 2026 | $3.28 | $3.30 | $3.14 | $3.16 | 799.22K |
| Aug 25, 2026 | $3.22 | $3.325 | $3.20 | $3.29 | 773.77K |
| Aug 24, 2026 | $3.32 | $3.37 | $3.13 | $3.19 | 678.66K |
| Aug 21, 2026 | $3.25 | $3.435 | $3.2223 | $3.30 | 1.14M |
| Aug 20, 2026 | $3.46 | $3.56 | $3.18 | $3.21 | 1.18M |
| Aug 19, 2026 | $3.31 | $3.50 | $3.30 | $3.48 | 1.75M |
| Aug 18, 2026 | $3.21 | $3.25 | $3.125 | $3.21 | 757.95K |
| Aug 17, 2026 | $3.21 | $3.305 | $3.19 | $3.22 | 1.17M |
| Aug 14, 2026 | $3.09 | $3.229 | $3.03 | $3.20 | 1M |
| Aug 13, 2026 | $3.26 | $3.28 | $3.09 | $3.10 | 1.32M |
The latest Smart Investors Daily articles mentioning CATX.
CATX research
Company profile and research snapshot.
Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 19, 2026 | BMO Capital | Outperform | — |
| Aug 14, 2026 | B of A Securities | Neutral | — |
| Aug 11, 2026 | Piper Sandler | Overweight | — |
| May 5, 2026 | Wedbush | Outperform | — |
| May 5, 2026 | BTIG | Buy | — |
No generated briefing is available yet.
SeekingAlpha · Sep 1, 2026
Perspective Therapeutics is rated Strong Buy on durable radiopharmaceutical data, $237M cash runway, and key 2026 catalysts. Click here to read more.
Benzinga · Aug 19, 2026
BMO Capital analyst David Lebowitz initiates coverage on Perspective Therapeutics (AMEX:CATX) with a Outperform rating and announces Price Target of $11.
Benzinga · Aug 14, 2026
B of A Securities analyst Alec Stranahan maintains Perspective Therapeutics (AMEX:CATX) with a Neutral and lowers the price target from $6 to $5.
Benzinga · Aug 11, 2026
Piper Sandler analyst Biren Amin maintains Perspective Therapeutics (AMEX:CATX) with a Overweight and lowers the price target from $16 to $14.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning CATX.
